Rheumatoid arthritis: problems of treatment at the present stage
https://doi.org/10.14412/1996-7012-2018-4-65-70
Abstract
The possibilities of rheumatoid arthritis therapy have been significantly expanded today. In addition to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), biologic agents (BAs), and a targeted synthetic DMARD, a control treatment strategy has been put into practice.
The paper demonstrates successes in the early prescription of csDMARD and the implementation of treat-to-target principles – to achieve the goal after 6 months in 50% of patients receiving subcutaneous methotrexate and 45% of those using a Leflunomide generic. During this therapy, there is a lower need for BAs and targeted synthetic DMARDs. The priority problem is to train general practitioners in methods for the early detection of RA and to set up schools for these patients.
About the Author
N. V. Chichasova
Department of Rheumatology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia; V.A. Nasonova Research Institute of Rheumatology.
Russian Federation
Russian Federation
Natalia Vladimirovna Chichasova.
8, Trubetskaya St., Build. 2, Moscow 119991.
34A, Kashirskoe Shosse, Moscow 115522.
References
1. Nasonova VA, Folomeeva OM, Erdes ShF. Social importance of rheumatic diseases in Russia. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2002;40(1):5-8. (In Russ.) doi: 10.14412/1995-4484-2002-740
2. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid Arthritis classification criteria/ An American College of Rheumatology / European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010 Sep;62(9):2569-81. doi: 10.1002/art.27584.
3. Smolen J, Aletaha D, Bijlsma J, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010 Apr;69(4):631-7. doi: 10.1136/ard.2009.123919. Epub 2010 Mar 9.
4. Nasonov EL, editor. Rossiiskie klinicheskie rekomendatsii. Revmatologiya [Russian clinical guidelines. Rheumatology]. Moscow: GEOTAR-Media; 2017. 456 p.
5. Smolen J, Landeve R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017 Jun;76(6):960-977. doi: 10.1136/annrheumdis-2016-210715. Epub 2017 Mar 6.
6. Van Steenbergen HW, Aletaha D, Beaart-van de Voorde LJ, et al. EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis. Ann Rheum Dis. 2017 Mar;76(3):491-496. doi: 10.1136/annrheumdis-2016-209846. Epub 2016 Oct 6.
7. Lard LR, Visser H, Speyer I, et al. Early versus delayed treatment un patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med. 2001 Oct 15;111(6):446-51.
8. Wiles NJ, Lunt M, Barrett EM, et al. Reduced disability at five years with early treatment of inflammatory polyarthritis. Results from a large observational cohort, using propensity models to adjust for disease severity. Arthritis Rheum. 2001 May;44(5): 1033-42.
9. Chichasova NV, Kanevskaya MZ, Imametdinova GR, et al. Long-term outcomes in rheumatoid arthritis in relation to the time after the initiationof basic antiinflammatory drug therapy. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2010;48(3):23-30. (In Russ.). doi: 10.14412/1995-4484-2010-439
10. Nasonov EL, Mazurov VI, Karateev DE, et al. Project: Recommendations on treatment of rheumatoid arthritis developed by All-russian public organization «Association of rheumatologists of Russia» – 2014 (Part 1). Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(5):477-94. (In Russ.). doi: 10.14412/1995-484-2014-477-494
11. Nasonov EL. Methotrexate in rheumatoid arthritis – 2015: new facts and ideas. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2015;53(4):421-33. (In Russ.). doi: 10.14412/1995-4484-2015-421-433
12. Donanue KE, Gartlenhar G, Jonas DE, et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med. 2008 Jan 15;148(2):124-34. Epub 2007 Nov 19.
13. Salliot C, Van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systemic literature research. Ann Rheum Dis. 2009 Jul;68(7):1100-4. doi: 10.1136/ard.2008.093690. Epub 2008 Dec 5.
14. Pincus T, Yazici Y, Sokka T, et al. Methotrexate as the «anchor drug» for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol. 2003 Sep-Oct;21 (5 Suppl 31):S179-85.
15. Molina JT, Garcia FJ, Alen JC, et al. Recommendations for the use of methotrexate in rheumatoid arthritis: up and down scaling of the dose and administration routes. Reumatol Clin. 2015 Jan-Feb;11(1):3-8. doi: 10.1016/j.reuma.2014.02.012. Epub 2014 Apr 18.
16. Visser K, Van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis. 2009 Jul;68(7):1094-9. doi: 10.1136/ard.2008.092668. Epub 2008 Nov 25.
17. Chichasova NV. The possibility of achieving the maximum effect in the controlled treatment of rheumatoid arthritis in real practice. Lechashchii vrach. 2015;(7): 29-33. (In Russ.).
18. Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/ European League Against Rheumatism Provisional Definition of remission in Rheumatoid Arthritis for clinical trials. Arthritis Rheum. 2011 Mar;63(3):573-86. doi: 10.1002/art.30129.
19. Kay J, Shoels MM, Dorner T, et al. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis. 2018 Feb;77(2): 165-174. doi: 10.1136/annrheumdis-2017-211937. Epub 2017 Sep 2.
Review
For citations:
Chichasova NV. Rheumatoid arthritis: problems of treatment at the present stage. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2018;12(4):65-70. (In Russ.) https://doi.org/10.14412/1996-7012-2018-4-65-70
Views:
2197
Email this article 